Vivos Therapeutics, Inc.
VVOS
$2.63
-$0.08-2.95%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -8.02% | -35.67% | 48.74% | 11.65% | -103.49% |
| Total Depreciation and Amortization | -1.37% | 0.69% | -0.68% | -2.01% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -58.11% | -49.83% | -1.34% | -34.43% | 129.06% |
| Change in Net Operating Assets | 82.89% | -19.56% | -294.39% | -11.48% | 27.07% |
| Cash from Operations | 29.78% | -37.37% | -21.14% | 8.44% | 1.86% |
| Capital Expenditure | 14.06% | -220.00% | 60.26% | 8.48% | -7.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 14.06% | -220.00% | 60.26% | 8.48% | -7.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -18.53% | -42.72% | 90.31% | -1.48% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 12.38% | -409.00% | 67.32% | 29.17% | -- |
| Cash from Financing | -19.36% | -48.82% | 103.58% | 1.88% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 91.39% | -113.79% | 343.39% | 47.79% | 122.17% |